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versus mesenchymal phenotype appears to be predictive of EGFR TKI 
-mediated growth inhibition in NSCLC tumor cell lines. These ﬁndings 
also suggest that EMT features may serve as potential biomarkers in 
predicting EGFR TKI clinical activity in NSCLC patients. Our recent 
studies have shown that inﬂammatory mediators are potent regulators 
of E-cadherin expression in lung cancer: IL-1β and PGE2 contribute 
to the downregulation of E-cadherin expression in NSCLC via distinct 
pathways that include induction of the transcriptional repressors ZEB-
1, Snail1 and Twist, and the PGE2 pathway upregulates the E-cadherin 
ubiquitin ligase, Hakai. Here we report on new studies that deﬁne the 
cellular elements within the TME that contribute these inﬂammatory 
mediators affecting expression and maintenance of E-cadherin, as 
well as other markers of EMT. These relationships are being assessed 
in organotypic model systems. Thus, TME-mediated inﬂammation 
provides a pathway to both EMT and resistance to targeted therapies in 
NSCLC. Full deﬁnition of these pathways will afford the opportunity to 
intervene in speciﬁc inﬂammatory events mediating lung tumorigenesis 
and resistance to therapy.
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In the post-genome era mouse is becoming an increasingly important 
tool of lung cancer research. The application of innovative technologies 
to generate accurate mouse models is likely to accelerate the discovery 
of new molecular targets and imaging biomarkers for the early detec-
tion of lung cancer (1,2). It remains to be seen which models will be 
most suitable for preclinical tests (3).
Comparative oncology of lung tumors
While mice and humans share many similarities in the molecular pa-
thology of lung tumorigenesis, there are also differences. Much of the 
earlier work focused on chemical carcinogenesis establishing parallel 
roles of many toxic chemicals as well as genetic and epigenetic altera-
tions in lung carcinogenesis of mice and humans (4). The incidence 
of spontaneous (and induced) lung tumors among the commonly used 
inbred strains varies markedly from high 61% in A/J mice to very 
low 6 % in C57Bl6 for males at 2 years. Unlike humans with four 
distinct lung cancer types that readily disseminate and reveal complex 
molecular genetics, mice are prone to pulmonary adenomas which are 
rare in humans or, infrequently, to adenocarcinomas, which seldom 
metastasize. Both of these mouse tumors are predominantly associated 
with Kras mutations. Premalignat lesions that are well characterized in 
the human airway epithelium and squamous cell carcinoma have been 
surprisingly difﬁcult to replicate in mice.
Does smoking cause lung cancer in mice? 
For decades, the credibility of mouse models suffered because of the 
lack of evidence that tobacco smoke, the main cause of lung cancers in 
humans, would lead to lung tumors in mice. Finally, lung tumors were 
induced reproducibly in A/J mice by exposing them to cigarette smoke 
for 5 months followed by a critically important 4 month recovery 
period (5). In a recent study, exposure of strain B6C3F1 female mice to 
life-time cigarette smoke (30 months) lead to 48% incidence of benign 
and malignant lung tumors through distinct genetic and epigenetic 
pathways (6). In comparison, 9.5% of control animals got tumors.
In contrast, cigarette smoke carcinogens such as the tobacco-speciﬁc 
nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
and benzo[a]pyrene (B[a]P) readily cause lung tumors in mice and have 
been widely used in studies on pathogenesis, chemoprevention and 
novel therapies (4).
Directing gene expression and cancer to lung
The development of methods for manipulating the mouse genome, 
combined with the sequencing of the mouse genome, has advanced 
our ability to develop a plethora of new, genetically engineered mouse 
(GEM) models for lung cancer. In many cases the genetic modiﬁcations 
are targeted to speciﬁc subsets of lung epithelial cells. The surfactant 
protein-C promoter directs the expression mainly into alveolar type II 
cells in the parenchyma, while CC10/CCSP promoters primarily target 
the nonciliated secretory (Clara) cells along the airways. The ﬁrst GEM 
lung cancer models involved the constitutive expression of SV40 Tag 
using these promoters, which resulted in aggressive adenocarcinomas 
without metastases (2). Many other transgenic mice followed using the 
same strategy, providing good models for observed ampliﬁcation and 
epigenetic modiﬁcation of the oncogenes. Same promoters are also 
used in many conditional mouse models. 
Conditional bitransgenic mouse models for lung adenocarcinoma, 
oncogene dependency and stem cells
Most oncogenic activating mutations in lung cancer are somatic, which 
prompted the generation of conditional models, where activation of ge-
netic events can be regulated both temporally and spatially (1). Muta-
tions in Ras oncogenes are commonly associated with both human and 
mouse adenocarcinomas. A tetracycline inducible K-Ras4G12D lung 
tumor model developed epithelial cell hyperplasia, adenomas and ad-
enocarcinomas after administration of doxycyclin. Interestingly, tumors 
completely regressed after withdrawal of doxycyclin demonstrating on-
cogene dependency. In a sporadic tumor model using Cre/loxP system a 
mutation can be directed to occur strictly in a set of differentiated cells 
while the genome of the adjacent cells remains unaltered. As a proof of 
principle, adeno-Cre-mediated expression of mutant alleles of oncogen-
ic K-RasG12D or K-RasG12V in the lung produced multiple adenomas 
and adenocarcinomas, revealing the precise role of Ras oncogenes in 
human lung carcinogenesis. Same approach helped to identify potential 
stem cells, BASCs in the peripheral lung.
Model for Small Cell Lung Cancer (SCLC) 
Almost all human SCLCs have sustained mutations of p53 and Rb1 
which rarely occur in mice. Somatic application of the Cre-loxP system 
was used to obtain primarily airway epithelium speciﬁc deletion of 
Rb1 and p53, which resulted in multiple tumors closely resembling 
human SCLCs (2). It is notable that the tumors demonstrated neuro-
endocrine features and had a marked capacity to metastasize to liver, 
brain, adrenal gland, bone and ovaries which mirrors the behavior of 
human SCLCs. Cell lines obtained from the mouse tumors also re-
vealed characteristics of SCLC including ampliﬁcation of L-myc. Other 
lung cancer models such as CC10-SV40 Tag/hASH1 bitransgenic or 
p18/Men1 deﬁcient mice have also been associated with pulmonary 
neuroendocrine tumors, but lack the typical histology and metastatic 
pattern of SCLC (7,8) 
Squamous cell carcinogenesis in mouse lung
Normally neither human nor mouse lung contains squamous epithe-
lium. However, the classic sequence of premalignant changes in human 
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airway epithelium consists of squamous metaplasia/dysplasia/carci-
noma in situ associated with invasive squamous cell carcinoma, which 
is very rare in mouse lung. Interestingly, the treatment with N-nitroso-
tris-chloroethylurea by skin painting of inbred mice induced pulmonary 
squamous cell carcinoma with premalignant changes in a strain-depen-
dent manner (9). Preliminary reports of GEM models include induction 
of the squamous differentiation program by overexpression of human 
keratin 14 in the airway epithelium (10), and involvement of Lkb1 with 
mouse squamous cell lung cancer (11). 
New directions for mouse models 
A newer generation of compound conditional mouse models are aimed 
to integrate varied features of existing models and develop new ones 
(1). For example, lung tumors in compound mice with conditional 
mutations in the K-ras proto-oncogene and different alleles of p53 
tumor suppressor gene are associated with stromal metaplasia and 
distant metastases characteristic of human lung adenocarcinomas. It has 
become obvious that human lung cancer has complex genetics which 
will require complex mouse models.
Recent studies of cross-species comparisons of cancer signaling have 
detected marked similarities in mouse and human lung tumorigenesis 
using gene proﬁling (12,13). This approach has also been extended 
to establish signatures for aggressive tumors of lung and other organs 
using SV40 transgenic mice (14). The reports provide a new molecular 
criterion for validating lung tumor models and potential clues for yet 
unappreciated pathways in human tumors.
Advances in imaging technologies parallel development of GEM. 
Discoveries through gene expression proﬁling in GEMs have led novel 
in vivo imaging techniques of mouse lung tumors using an optical 
probe activated cathepsin proteases (15). Yet another approach has been 
the generation of a conditional luciferase reporter mouse that enables 
bioluminescence imaging of tumorigenesis (16). 
The most frequently used model for chemoprevention studies has 
been the A/J mouse. Recent studies have incorporated the mutant A/J 
mouse with genetic alterations in p53, K-ras or Ink4A/Arf, which are 
commonly involved in human lung tumorigenesis and facilitate the 
adenoma-carcinoma assessment (17,18). Moreover genetic signatures 
for such chemopreventive agents as green tea and budenoside and 
treatment with Geﬁtinib have been established using cDNA microarray 
analysis on mouse lung tumors (19, 20). 
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Background. 
The expression of the catalytic subunit of human telomerase (hTERT) 
produces telomerase activity and circumvents telomere-based repli-
cative aging in normal cells. We have used hTERT to immortalize a 
variety of human cell types including skin keratinocytes and ﬁbroblasts, 
muscle satellite cells, breast epithelial and stromal ﬁbroblast cells, and 
both corneal epithelial cells and ﬁbroblasts (keratocytes). Corneal epi-
thelial cells expressing introduced hTERT require growth on collagen 
IV while both breast epithelial cells and skin keratinocytes require 
feeder layers to prevent a premature p16-induced growth arrest due to 
inadequate culture conditions. Human corneal and skin cells expressing 
hTERT can be used to form organotypic (3D) cultures. Stromal cells 
are mixed with collagen type I, permitted to contract, and then placed 
on a porous membrane in a transwell dish. The hTERT immortalized 
epithelial cells are then layered on top of the stromal cell/collagen 
plug the cells are exposed to air instead of being submerged in culture 
medium. Such organotypic cultures express differentiation-speciﬁc 
proteins, demonstrating that hTERT does not grossly alter the differen-
tiation phenotype. 
Immortalization of Human Bronchial Epithelial Cells (HBECs) 
with CDK4 and hTERT. 
The optimal culture conditions to immortalize human bronchial 
epithelial cells (HBEC) with only ectopically introduced hTERT have 
not been determined, and thus we expressed both hTERT and cdk4 (to 
bypass upregulated p16). In organotypic (3D) culture, cdk4 + hTERT 
immortalized human bronchial epithelial cells are placed on top of 
collagen plugs contracted by normal human lung ﬁbroblasts and then 
exposed to an air-medium interface and allowed to differentiate. One 
immortal clone HBEC3-KT is able to differentiate into both mucous 
(goblet) and ciliated epithelial cells when placed in 3D cultures. Thus 
these cells may have wide utility in investigating normal morphogen-
esis and diseases associated with lung dysfunction. In addition, these 
cells also provide a novel cellular resource to study the molecular 
pathogenesis of lung cancer. 
Characterization of HBECS. 
In addition to studying their ability to differentiate in 3D organotypic 
culture, we have performed expression proﬁling (Affymetrix and Il-
lumina arrays) and Q RT-PCR expression proﬁling of the immortalized 
compared to non immortal HBECs. We have deﬁned gene expression 
signatures, of a panel of 30 stem cell genes that show dramatic expres-
sion changes with immortalization (such as changes in Notch1, Hey2, 
Jag1, DLL1, Sox2, and Smo).
Isogenic Oncogenic Manipulation of HBECs. 
In the HBEC3-KT immortalized cells we have stably knocked down 
p53 using a shRNA and also over-expressed the transforming onco-
gene, K-rasV12. The HBEC3-KT cells with knockdown of p53 and 
over-expression of K-rasV12 invade into the ﬁbroblast stromal matrix 
